Facharzt FMH Medizinische Onkologie

Facharzt FMH Medizinische Onkologie (Switzerland)

Systemic Therapies Immuno OncologyEnglish
Exam overview

Practice session

What is the key biological and pharmacological difference between anti-PD-1 monoclonal antibodies (e.g., Pembrolizumab, Nivolumab) and anti-PD-L1 monoclonal antibodies (e.g., Atezolizumab, Durvalumab)?

Loading your practice session…